

# Mauro Ragonese

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3314888/publications.pdf>

Version: 2024-02-01

16  
papers

157  
citations

1306789

7  
h-index

1199166

12  
g-index

16  
all docs

16  
docs citations

16  
times ranked

257  
citing authors

#	ARTICLE	IF	CITATIONS
1	ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk BCG failure non muscle invasive bladder cancer: 3 years follow-up outcomes. BMC Cancer, 2018, 18, 1224.	1.1	51
2	Can Neutrophil-to-Lymphocyte ratio predict the response to BCG in high-risk non muscle invasive bladder cancer?. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2019, 45, 315-324.	0.7	18
3	Implementation of frailty preoperative assessment to predict outcome in patients undergoing urological surgery: a systematic review and meta-analysis. BJU International, 2021, 127, 507-517.	1.3	17
4	Chemoablation with Intensive Intravesical Mitomycin C Treatment: A New Approach for Non-muscle-invasive Bladder Cancer. European Urology Oncology, 2019, 2, 576-583.	2.6	14
5	Mechanisms of Resistance to Second-Generation Antiandrogen Therapy for Prostate Cancer: Actual Knowledge and Perspectives. Medical Sciences (Basel, Switzerland), 2022, 10, 25.	1.3	10
6	An Italian multicenter analysis of emergency admissions and treatment of upper tract urolithiasis during the lockdown and reopening phases of the COVID-19 pandemic: Are we ready for a second wave of the outbreak?. International Journal of Urology, 2021, 28, 950-954.	0.5	9
7	Improved Non-Invasive Diagnosis of Bladder Cancer with an Electronic Nose: A Large Pilot Study. Journal of Clinical Medicine, 2021, 10, 4984.	1.0	9
8	The bladder epicheck test and cytology in the follow-up of patients with non-muscle-invasive high grade bladder carcinoma.. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 108.e19-108.e25.	0.8	8
9	Second-Line Conservative Device-Assisted Intravesical Treatment in Selected Patients With Recurrent High-Risk Non-muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2021, 19, e100-e119.	0.9	6
10	The Role of Bladder Epicheck Test In Follow-Up of Patients with Non-Muscle Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2022, 20, e271-e275.	0.9	6
11	Psychological aptitude for surgery: The importance of non-technical skills. Urologia, 2019, 86, 45-51.	0.3	3
12	Immediate ileal ureter replacement for ureteral avulsion during ureteroscopy. IJU Case Reports, 2020, 3, 241-243.	0.1	2
13	A gravity-assisted approach to the management of urinary diversion: 99mTc-MAG3 diuresis renography with F-18 NaF method. Annals of Nuclear Medicine, 2021, 35, 1127-1135.	1.2	2
14	Laser technology in urologic oncology. Urologia, 2022, 89, 338-346.	0.3	2
15	The Occult Urothelial Cancer. Urologia, 2016, 83, 55-60.	0.3	0
16	Synchronous Partial Nephrectomy and Renal Artery Aneurysm Repair in Bilateral Renal Cancers: Case Report and Literature Review. Urologia Internationalis, 2021, 105, 525-530.	0.6	0